Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INO-3605 · 1 trial · 1 indication
Frequency and severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events
| Arm | Type | Description |
|---|---|---|
| Arm A - 0.9mg of INO-3605 | EXPERIMENTAL | - |
| Arm B - 0.9mg of INO-3609 | EXPERIMENTAL | - |
| Arm C- 0.9mg of INO-3401 | EXPERIMENTAL | - |
| Arm D- 0.3mg of INO-3609 | EXPERIMENTAL | - |
| Arm E - 0.45mg each INO-3605 , INO-3609 | EXPERIMENTAL | - |
| Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609 | EXPERIMENTAL | - |
| Arm G - 0.9mg of INO-3609 | EXPERIMENTAL | - |
| Arm H - 0.9mg of INO-3609 | EXPERIMENTAL | - |
| Arm I - Seasonal influenza vaccine | ACTIVE_COMPARATOR | - |
| Arm J - 1.8mg of INO-3609 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INO-3605 | BIOLOGICAL | 0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| INO-3609 | BIOLOGICAL | 0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| INO-3401 | BIOLOGICAL | 0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| INO-3605 AND INO-3609 | BIOLOGICAL | 0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| INO-3510 | BIOLOGICAL | 0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| Seasonal Influenza vaccine | BIOLOGICAL | 0.5ml of vaccine delivered IM |
Inclusion Criteria: * Written informed consent in accordance with institutional guidelines. If required by local law, candidates must also authorize the release and use of protected health information (PHI); * Adults of either gender 18-55 years of age at entry; * Healthy subjects as judged by the ...
INO-3605 is an investigational monoclonal antibody developed by Inovio Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial involving healthy adult volunteers. The specific disease indication for INO-3605 has not been publicly disclosed.
INO-3605 is being developed by Inovio Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol INO. The company sponsored the Phase 1 study of the candidate.
INO-3605 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational product and has not been approved by the FDA.
INO-3605 was evaluated in the completed Phase 1 trial NCT01405885, titled "A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus." The study enrolled 116 healthy adult volunteers in the United States and used an active-controlled design.
The Phase 1 trial NCT01405885 was an active-controlled study that enrolled 116 healthy volunteers aged 18 years and older in the United States. It was not randomized and not double-blinded, and it has been completed.